Literature DB >> 33855105

RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of in vitro Transcribed mRNA in Human Whole Blood.

Akm Ashiqul Haque1, Petra Weinmann1, Sumit Biswas1, Rupert Handgretinger2, Markus Mezger2, Michael S D Kormann1, Justin S Antony1,2.   

Abstract

The mRNA therapeutics is a new class of medicine to treat many various diseases. However, in vitro transcribed (IVT) mRNA triggers immune responses due to recognition by human endosomal and cytoplasmic RNA sensors, but incorporation of modified nucleosides have been shown to reduce such responses. Therefore, an assay signifying important aspects of the human immune system is still required. Here, we present a simple ex vivo method called 'RNA ImmunoGenic Assay' to measure immunogenicity of IVT-mRNAs in human whole blood. Chemically modified and unmodified mRNA are complexed with a transfection reagent (TransIT), and co-incubated in human whole blood. Specific cytokines are measured (TNF-α, INF-α, INF-γ, IL-6 and IL-12p70) using ELISAs. The qPCR analysis is performed to reveal the activation of specific immune pathways. The RNA ImmunoGenic Assay provides a simple and fast method to detect donor specific - immune response against mRNA therapeutics. Graphic abstract: Schematic representation of RNA ImmunoGenic Assay.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Cytokines; IVT-mRNA; Immunogenicity; Whole blood assay; cmRNA

Year:  2020        PMID: 33855105      PMCID: PMC8032499          DOI: 10.21769/BioProtoc.3850

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  4 in total

Review 1.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

2.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.

Authors:  Katalin Karikó; Hiromi Muramatsu; János Ludwig; Drew Weissman
Journal:  Nucleic Acids Res       Date:  2011-09-02       Impact factor: 16.971

3.  Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification.

Authors:  Sriram Vaidyanathan; Krist T Azizian; A K M Ashiqul Haque; Jordana M Henderson; Ayal Hendel; Sabrina Shore; Justin S Antony; Richard I Hogrefe; Michael S D Kormann; Matthew H Porteus; Anton P McCaffrey
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-30       Impact factor: 8.886

4.  Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.

Authors:  Justin S Antony; Alexander Dewerth; Ashiqul Haque; Rupert Handgretinger; Michael S D Kormann
Journal:  Mol Cell Pediatr       Date:  2015-11-20
  4 in total
  1 in total

Review 1.  Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.

Authors:  Nusrat Zahan Rouf; Sumit Biswas; Nawseen Tarannum; Labiba Mustabina Oishee; Mutia Masuka Muna
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.